In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Faux foie gras firm forms foodie panel
In Paris, cultivated meat startup Gourmey has formed what it claims is the culinary industry’s first-ever advisory board dedicated to cultivated meat.
The panel...
Celleste Bio secures $4.5 million for cell-cultured cocoa
In Israel, cell cultured cocoa startup Celleste Bio has raised $4.5 million in a seed funding round. The funds will boost the company's research...
Wrapped up: Origami inspires paperboard packaging solution
In Finland, researchers from VTT and Aalto University are applying origami, the ancient Japanese art of paper folding, to the plastics waste crisis.
Led...